Isatuximab in Patients With Monoclonal Gammopathy of Renal Significance
Status:
Not yet recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see whether Isatuximab can help improve kidney function of
participants with MGRS. Isatuximab is approved by the Food and Drug Administration (FDA) for
the treatment of adult patients with multiple myeloma, but it is not approved by the FDA to
treat MGRS. This means that the use of isatuximab in this study is considered
'investigational'.